Advertisement

Topics

Pulse Biosciences Announces Treatment of First Patient in Study to Evaluate the Safety and Efficacy of Novel Nano-Pulse Stimulation Technology for Seborrheic Keratosis Lesions

08:00 EDT 6 Jun 2017 | Businesswire
This article has expired, however you can still download the PDF.
Preview:
Pulse Biosciences, Inc. (Nasdaq:PLSE), a medical technology company developing a therapeutic tissue treatment platform based on its proprietary Nano-Pulse Stimulation (NPS) technology, today announced treatment of the first pat...

Other Sources for this Article

Pulse Biosciences, Inc.
Investors:
Brian Dow
SVP and Chief Financial Officer
IR@pulsebiosciences.com
or
The Trout Group
Mike Zanoni, 646-378-2924
mzanoni@troutgroup.com
or
Media:
Sam Brown, Inc.
Christy Curran, 615-414-8668
christycurran@sambrown.com

NEXT ARTICLE

More From BioPortfolio on "Pulse Biosciences Announces Treatment of First Patient in Study to Evaluate the Safety and Efficacy of Novel Nano-Pulse Stimulation Technology for Seborrheic Keratosis Lesions"

Quick Search
Advertisement
 

Relevant Topics

Dermatology
Acne Dermatology Eczema Psoriasis Wound Care Dermatology is the medical specialty concerned with the diagnosis and treatment of skin disorders (Oxford Medical Dictionary). As well as studying how the skin works, dermatology covers...

Wound management
Anything that breaks the skin is a wound because when the skin is broken, there's a risk of germs getting into the body and causing an infection. Follow and track Wound Care News on BioPortfolio: Wound Car...